Publications by authors named "C M Florkowski"
Aims: Point-of-care (POC) high-sensitivity troponin (hs-cTn) assays within a clinical pathway may safely reduce length of stay (LoS) for patients presenting to the emergency department (ED) with possible acute myocardial infarction (AMI). In this early report, we present the first evaluation of a POC hs-cTn in real-life care.
Methods And Results: In adult patients presenting to ED investigated for possible AMI, we compared the LoS in patients assessed with a troponin in the 8 weeks before (usual-care phase) and the 8 weeks following introduction of the Siemens Atellica VTLi POC hs-cTnI for decision-making (intervention phase).
Article Synopsis
- Primary aldosteronism (PA) is a significant cause of hypertension, and familial hyperaldosteronism type 1 (FH-1) is a hereditary form that can lead to severe health issues, making early detection important.
- A study analyzed genetic testing data for FH-1 in New Zealand from April 2010 to October 2023, revealing that only 147 tests were conducted, with a positive result in 12.9% of cases and significant variations in testing rates by region.
- Although testing rates for FH-1 have increased over the years, they are still considered low, indicating a need for more awareness and testing, especially for individuals diagnosed with PA at a young age or those with a family
Objectives: The Siemens Point-of-Care Testing (POC) Atellica VTLi high-sensitivity troponin I (hsTnI) device has been previously validated. Verification independently provides evidence that an analytical procedure fulfils concordance with laboratory assays, imprecision, and hemolysis interference requirements.
Methods: Five whole blood samples spanning the measuring interval were analysed 20 times in succession.